1h Free Analyst Time
About this market
Speak directly to the analyst to clarify any post sales queries you may have.
Regulatory agencies are granting special drugs designations for the development of drugs for the treatment of infectious diseases, including those used for the treatment of staphylococcal infection. Special drug designations offer incentives for the development of new drugs for the treatment which is encouraging more and more manufacturers to invest in the development of drugs, which in turn is driving the market. The analysts have predicted that the staphylococcal infection drugs market will register a CAGR of nearly 3% by 2023.
Market Overview
Increasing incidence of staphylococcal infections
The emergence of antibiotics resistant strains has led to increased incidence of staphylococcal infections. Skin and soft tissue infections are the most common type of infections caused by staphylococcal. Thus, rising incidence of staphylococcal infections is a major driver contributing to the market growth.
Lack of vaccines and new drug classes
Unlike most of the infectious diseases that can be prevented by vaccines, there is no approved vaccine for the prevention of staphylococcal infections. The rapid evolution of the bacteria responsible along with the following factors pose a major hurdle to the development of vaccines against staphylococcal infections.
For the detailed list of factors that will drive and challenge the growth of the staphylococcal infection drugs market during the 2019-2023, view the full report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck & Co. Inc. and Pfizer Inc the competitive environment is quite intense. Factors such as the increasing incidence of staphylococcal infections and special drug designations, will provide considerable growth opportunities to staphylococcal infection drugs manufactures. Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc. are some of the major companies covered in this report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Executive Summary
Global Staphylococcal Infection Drugs Market 2019-2023The author of the report recognizes the following companies as the key players in the global staphylococcal infection drugs market: Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the expanding R&D of novel therapies.”
According to the report, one of the major drivers for this market is the increasing incidence of staphylococcal infections.
Further, the report states that one of the major factors hindering the growth of this market is the lack of vaccines and new drug classes.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Allergan Plc
- Bayer AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Pfizer Inc.